mNOX-E36, a CCL2 inhibitor, can suppress the recruitment of MoMFs to the liver in CCl4-induced liver fibrosis models and methionine–choline-deficient diet (MCD)-induced NASH model. This evidence concerns the gene CCL2 and Hepatic fibrosis.